Herregods L, Rolly G, Van Belleghem Y, Van Nooten G
Section of Cardiac Anaesthesia, University Hospital, Gent, Belgium.
Anaesthesia. 1994 Aug;49(8):719-22. doi: 10.1111/j.1365-2044.1994.tb04409.x.
R 80122 is a new short-acting phosphodiesterase type III inhibitor. In a preliminary investigation, three patients, scheduled for coronary artery bypass surgery, were given R 80122 after weaning from cardiopulmonary bypass. Two patients received 10 micrograms.kg-1.min-1 for 10 min as a loading infusion followed by a 5 micrograms.kg-1.min-1 maintenance dose. One patient received a 20 micrograms.kg-1.min-1 for 10 min loading infusion followed by a 10 micrograms.kg-1.min-1 maintenance infusion. After weaning from cardiopulmonary bypass and during the administration period, no arrhythmias or cardiac ischaemia were detected. The administration of R 80122 improved the haemodynamic profile with an increase in cardiac output, a decrease in systemic vascular resistance and a stable heart rate and mean arterial blood pressure. These preliminary results indicate that R 80122 possesses positive inotropic activity in combination with vasodilating properties.
R 80122是一种新型短效III型磷酸二酯酶抑制剂。在一项初步研究中，三名计划进行冠状动脉搭桥手术的患者在体外循环撤机后接受了R 80122治疗。两名患者以10微克·千克⁻¹·分钟⁻¹的剂量静脉滴注10分钟作为负荷剂量，随后以5微克·千克⁻¹·分钟⁻¹的剂量维持输注。一名患者以20微克·千克⁻¹·分钟⁻¹的剂量静脉滴注10分钟作为负荷剂量，随后以10微克·千克⁻¹·分钟⁻¹的剂量维持输注。在体外循环撤机后及给药期间，未检测到心律失常或心肌缺血。R 80122的给药改善了血流动力学状态，心输出量增加，全身血管阻力降低，心率和平均动脉血压稳定。这些初步结果表明，R 80122具有正性肌力活性并兼具血管舒张特性。
